TY - JOUR
T1 - Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum
AU - Nitta, Atsumi
AU - Ogihara, Yoshiko
AU - Onishi, Joji
AU - Hasegawa, Takaaki
AU - Furukawa, Shoei
AU - Nabeshima, Toshitaka
N1 - Funding Information:
This work was supportedi,n part,b y an SRF Grant for Biomedical Research,b y a Grant-in-Aid for Science Re-searchf rom the Ministry of Edusation,S cience,a nd Culture of Japan (No, (37557009b),y a grantf or Gerontological Science Researchf rom the Ministry of Health and Welfareo f Japan( No. 91A -2406).a ndby a gramf rom th emorialF oundation.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1996/6/20
Y1 - 1996/6/20
N2 - We have reported that the continuous infusion of anti-nerve growth factor (NGF) monoclonal antibody into the septum of rats produces neuronal dysfunction in the cholinergic system. Propentofylline has potent stimulatory effects on NGF synthesis/secretion in mouse astrocytes in vitro. To investigate the pharmacological effects of propentofylline, we used an animal model of dementia in which anti-NGF antibody was infused into the septum for 16 days via a mini-osmotic pump. The rats were treated with propentofylline orally once a day throughout the period during which performance in learning and memory tasks was observed. In the vehicle-treated dementia rats, learning and memory ability and choline acetyltransferase and cholinesterase activity were reduced compared to values in the control rats. The administration of propentofylline prevented the decreased learning capacity and the deficit in cholinergic marker enzyme activities. These results suggest that the use of NGF stimulators may provide a new approach to the treatment of dementia.
AB - We have reported that the continuous infusion of anti-nerve growth factor (NGF) monoclonal antibody into the septum of rats produces neuronal dysfunction in the cholinergic system. Propentofylline has potent stimulatory effects on NGF synthesis/secretion in mouse astrocytes in vitro. To investigate the pharmacological effects of propentofylline, we used an animal model of dementia in which anti-NGF antibody was infused into the septum for 16 days via a mini-osmotic pump. The rats were treated with propentofylline orally once a day throughout the period during which performance in learning and memory tasks was observed. In the vehicle-treated dementia rats, learning and memory ability and choline acetyltransferase and cholinesterase activity were reduced compared to values in the control rats. The administration of propentofylline prevented the decreased learning capacity and the deficit in cholinergic marker enzyme activities. These results suggest that the use of NGF stimulators may provide a new approach to the treatment of dementia.
UR - http://www.scopus.com/inward/record.url?scp=0030594569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030594569&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(96)00133-1
DO - 10.1016/0014-2999(96)00133-1
M3 - Article
C2 - 8831096
AN - SCOPUS:0030594569
SN - 0014-2999
VL - 307
SP - 1
EP - 6
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -